Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07245316

Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial

This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Ductal Carcinoma in Situ of the Breast Adenocarcinoma Breast Carcinoma In Situ Carcinoma Carcinoma in Situ Carcinoma, Intraductal, Noninfiltrating Neoplasms Neoplasms by Histologic Type Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial

Age range

35 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Inclusion criteria:
  • Female patients aged ≥35 years.
  • Diagnosed with atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) on core-needle biopsy, vacuum-assisted biopsy, or excisional biopsy.
  • Immunohistochemistry (IHC) performed on biopsy specimens confirming estrogen receptor (ER), progesterone receptor (PR), and HER2 status; eligible only if the ER Allred total score is ≥7 and HER2 status is negative.
  • All low- and intermediate-grade nuclear grades included; for high-grade lesions, only patients with a Ki-67 index ≤20% are eligible.
  • Lesion not definitely palpable on physical examination at diagnosis.
  • No prior breast surgery for ipsilateral or contralateral breast cancer, and no synchronous contralateral breast cancer.
  • Not diagnosed with pregnancy-associated breast cancer or breast cancer detected during lactation.
  • Negative serum or urine β-hCG prior to enrollment.
  • Provided written informed consent to participate in the study.
  • Exclusion criteria:
  • Pregnant patients.
  • Patients with clinically significant psychiatric disorders (e.g., major depressive disorder) or those currently receiving psychiatric or antipsychotic medications.
  • Concomitant diagnosis of invasive breast cancer.
  • Evidence of axillary lymph node metastasis.
  • Carriers of BRCA1/2 mutations.
  • Male patients.
  • History of diagnosis or treatment for breast cancer.
  • Presence or history of other malignancies besides breast cancer.
  • Concomitant diagnosis of pleomorphic LCIS.

Treatment and study plan

Avoiding surgery

Procedure

Avoiding surgery in hormone-receptor positive atypical ductal hyperplasia and in-situ carcinoma treated with endocrine treatment

Primary outcomes

  1. 5 year ipsilateral breast cancer incidence rate

    Time frame: 5 years after the last patient enrollment

    This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.

Secondary outcomes

  1. Adjuvant chemotherapy rate

    Time frame: 5 years after the last patient enrollment

    5 year adjuvant chemotherapy rate

  2. invasive CBC rate

    Time frame: 5 years after the last patient enrollment

    5 year invasive contralateral breast cancer rate

  3. OS

    Time frame: 5 years after the last patient enrollment

    5 year overall survival

  4. BCSS

    Time frame: 5 years after the last patient enrollment

    5 year breast cancer specific survival

  5. Change in health-related quality of life assessed by EORTC QLQ-C30

    Time frame: At baseline, at 2 years, and at 5 years after the last patient enrollment

    HRQoL will be evaluated using the EORTC QLQ-C30. Scores range from 0-100. Higher functional/global health scores indicate better QoL, while higher symptom scores indicate greater symptom burden.

  6. Change in breast cancer-specific quality of life assessed by EORTC QLQ-BR23

    Time frame: At baseline, at 2 years, and at 5 years after the last patient enrollment

    Breast cancer-specific QoL will be assessed using the EORTC QLQ-BR23. Scores range from 0-100. Higher functional scores indicate better QoL; higher symptom scores indicate worse symptom burden.

Other outcomes

  1. Prognostic differences in invasive breast cancer progression according to age and type of endocrine therapy

    Time frame: 5 years after the last patient enrollment

    Invasive breast cancer progression will be evaluated according to age at diagnosis and type of endocrine therapy. The proportion of participants who develop histologically confirmed invasive breast cancer during follow-up will be compared across subgroups defined by age and endocrine therapy regimen (tamoxifen, aromatase inhibitor, or combination with ovarian function suppression).

  2. Adverse events associated with endocrine therapy and ovarian function suppression

    Time frame: From initiation of endocrine therapy to treatment discontinuation or last follow-up (up to 5 years after enrollment)

    Incidence and severity of adverse events related to endocrine therapy and/or ovarian function suppression, graded according to CTCAE criteria.

  3. Direct medical cost of active monitoring compared with standard therapy

    Time frame: 5 years after the last patient enrollment

    Mean total direct medical cost (USD) incurred during 5-year follow-up will be compared between the active monitoring protocol and standard surgical management based on institutional billing data.

  4. Incremental cost-effectiveness ratio (ICER) of active monitoring compared with standard therapy

    Time frame: 5 years after last patient enrollment.

    Cost-effectiveness will be evaluated by the incremental cost-effectiveness ratio (ICER), calculated as cost per quality-adjusted life-year (QALY) gained for active monitoring versus standard therapy.

  5. Change in circulating tumor DNA (ctDNA) detectability from baseline to surgery among participants who undergo surgery for invasive progression

    Time frame: Baseline and at time of surgery

    Paired assessment of ctDNA detectability (present/absent) at baseline (diagnosis) and at the time of surgery among participants who progress to invasive breast cancer. Peripheral blood (20 mL) is collected at both time points.

  6. Longitudinal detectability of circulating tumor DNA (ctDNA) at annual follow-up compared with baseline

    Time frame: Baseline (Day 1) and annually through study completion (up to 5 years)

    Assessment of ctDNA detectability (present/absent) at baseline and at annual follow-up visits in all enrolled participants. Peripheral blood (20 mL) is collected at each time point.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeong Eon Lee, MD, PhD

CONTACT

[email protected]

+82-10-9933-0260

Sponsors and collaborators

Lead sponsor

Jeong Eon Lee

Other

Registry information

Acronym: ASAIN

Important dates

Study start
2025
Primary completion
2032
Study completion
2032
First posted
Nov 24, 2025
Registry last updated
Nov 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.